Gachon University Gil Medical Center
| Republic of Korea | Turkey | Austria | |
| Stem Cell Therapy | from $730 | from $7,200 | from $8,500 |
| Plasmapheresis | from $4,200 | from $1,200 | from $2,000 |
| Stem cell therapy for ALS (amyotrophic lateral sclerosis) | - | from $30,000 | from $60,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Amyotrophic lateral sclerosis treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Amyotrophic lateral sclerosis treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Amyotrophic lateral sclerosis treatment journey.
Dr. Byung-hee Lee has 42 years of experience of experience and has performed 900+ treatments, specializing in innovative approaches for neurological conditions.
The doctor is a leading neurologist in South Korea, specializing in epilepsy treatment. Currently, the doctor serves as the Head of the Neurology Department at Yonsei Severance Hospital.
The doctor graduated from Yonsei University College of Medicine and is an active member of several professional organizations, including The Korean Epilepsy Society, The Korean Neurological Association, and The Korea Medical Association.
South Korea offers Neuronata-R, the world first licensed stem cell therapy for ALS. This autologous mesenchymal stem cell treatment is currently only available at specialized Korean university hospitals. It aims to slow disease progression through intrathecal injections into the spinal fluid.
Bookimed Expert Insight: While many countries offer experimental stem cell treatments, South Korea stands out because Neuronata-R is officially licensed for clinical use. Facilities like RE:YOUTH specialize in arterial delivery to ensure cells reach target organs. This regulatory approval provides a level of official oversight rarely found in other global stem cell hubs.
Patient Consensus: Patients note that while Korean clinics offer fast access to new treatments, the logistical effort is high. They suggest prioritizing established hospitals over smaller clinics to ensure comprehensive multidisciplinary support and genuine clinical trials.
South Korean tertiary hospitals provide specialized amyotrophic lateral sclerosis (ALS) care through dedicated clinics and multidisciplinary teams. Leading centers like Hanyang University Hospital and Severance Hospital integrate neurology, rehabilitation, and respiratory support. These institutions also offer innovative treatments including stem cell therapy and plasmapheresis.
Bookimed Expert Insight: Hospital volume is a key indicator of diagnostic precision in Korea. Severance Hospital manages over 1.6 million outpatients annually. Dr. Yeon Jung Kim at Asan Medical Center brings international experience from New York Presbyterian. These high-volume centers often provide access to government programs that reduce out-of-pocket patient costs.
Patient Consensus: Patients emphasize reaching out to specialized neurology departments at major Seoul centers to confirm multidisciplinary team availability. Many note that connecting with local patient advocacy groups helps navigate the specific care pathways in South Korea.
International health insurance rarely covers NeuroNata-R or stem cell injections in South Korea. Insurers typically classify these regenerative therapies as experimental or investigational. While South Korea conditionally approved NeuroNata-R for ALS, it lacks full approval from the United States Food and Drug Administration.
Bookimed Expert Insight: Patient volume data suggests many travel to South Korea for arterial stem cell delivery. This method, available at clinics like RE:YOUTH, targets organs directly rather than using traditional IV. Doctors like Dr. Byung-hee Lee focus on this precision, yet patients should still plan for out-of-pocket costs.
Patient Consensus: Patients note that while the medical bureaucracy is complex, having detailed clinical reports in English is vital. They often emphasize that navigating these costs alone is the most stressful part of the journey.
Palliative care for ALS in South Korea emphasizes intensive medical interventions within tertiary hospitals. Practices prioritize invasive airway management and procedural nutrition support. Approximately 35% of patients undergo tracheostomy. This rate is significantly higher than in most Western healthcare systems.
Bookimed Expert Insight: Clinical data reveals South Korea serves as a major hub for complex neurology. Severance Hospital alone manages 1.6 million outpatients annually. This high volume supports a massive infrastructure for technical interventions like tracheostomies. However, ALS is not currently eligible for formal hospice benefits under Korean law. Patients often transition to high-capacity centers like Gachon University Gil Medical Center for advanced support.
Patient Consensus: Patients note that family members often lead daily care for feeding tubes after discharge. Most local discussions regarding long-term management occur on Korean-language medical forums rather than international platforms.
Standard evaluations for ALS in South Korea typically require 1 week. Treatment cycles vary by protocol, with single stem cell therapy cycles lasting 9 to 10 days. Advanced protocols or drug infusions like Edaravone often require stays of 10 to 14 days per session.
Bookimed Expert Insight: While major centers like Severance Hospital manage massive patient volumes, specialized clinics focus on specific delivery methods. RE:YOUTH Clinic uses a targeted arterial injection method for stem cell therapy. This emphasizes that treatment time is not just about the drug used. It depends on the complexity of the delivery technology available at the clinic.
Patient Consensus: Patients note it is helpful that major centers have dedicated international teams. These coordinators help speed up the process so evaluations start immediately upon arrival.
South Korean hospitals provide comprehensive remote follow-up for ALS patients using advanced telemedicine and electronic health record systems. Facilities like Severance Hospital utilize digital imaging and smart building technology to monitor recovery. Patients receive detailed bilingual documentation and instructions to ensure seamless care continuity with local physicians.
Bookimed Expert Insight: While many facilities offer standard follow-up, choosing a clinic with integrated EHRs and AI like Severance Hospital is a game-changer. Their massive volume of 1.6 million outpatients yearly helps them refine remote monitoring protocols. This digital infrastructure ensures your home-country doctor receives precise data, preventing any gaps in your ALS management plan.
South Korea offers Neuronata-R. This autologous bone marrow-derived stem cell therapy has conditional approval for ALS. Specialists also perform arterial stem cell therapy and direct infusion. Major centres like Severance Hospital and RE:YOUTH facilitate these treatments. They use JCI-accredited or Newsweek-ranked facilities across Seoul and Incheon.
Bookimed Expert Insight: Neuronata-R is the standard approved therapy. RE:YOUTH clinic distinguishes itself by limiting intake to two patients daily. This high-focus model lets Dr Byung-hee Lee customise arterial infusion protocols. This approach is rare, even in a major hub like Seoul. It typically suits patients seeking intensive, individualised interventional care.
South Korea offers Neuronata-R, a stem cell therapy for amyotrophic lateral sclerosis not yet approved in Australia. This treatment uses autologous bone marrow-derived mesenchymal stem cells. The Ministry of Food and Drug Safety granted it conditional approval in 2013 to slow disease progression.
Bookimed Expert Insight: While most international centres use spinal injections, specific Korean clinics like RE:YOUTH specialise in arterial stem cell delivery. This method aims for more direct targeting of neurological tissue. Dr Byung-hee Lee at this clinic is a founding member of the Korean Society of Interventional Neurology. He brings rare vascular expertise to ALS care.
Patient Consensus: Patients note South Korea provides rapid access to clinical trial options and regenerative therapies. They recommend getting written English summaries of all procedures. These summaries help Australian neurologists manage follow-up care.
Major South Korean tertiary hospitals provide ALS care through integrated neurology and rehabilitation teams. Facilities like Severance Hospital and Hanyang University Hospital specialise in combined therapy models. These centres coordinate neurologists, pulmonologists, and physiotherapists to manage motor neuron symptoms. This approach aims to improve quality of life.
Bookimed Expert Insight: Large university hospitals like Severance manage massive patient volumes. In contrast, smaller specialised clinics such as RE:YOUTH restrict intake to 2 patients daily. This allowing patients to choose between high-capacity research environments and high-attention VIP settings.
Korean ALS centres prioritise long-term survival through invasive ventilation more frequently than Western clinics. While standards often focus on palliative care, specialists here frequently use tracheostomies. This approach extends life significantly for patients facing respiratory failure within JCI-accredited facilities like Severance Hospital.
Bookimed Expert Insight: South Korea leads in combining conventional neurology with regenerative techniques. Major centres like Severance Hospital hold JCI and KOIHA accreditations. Meanwhile, smaller specialised clinics like RE:YOUTH offer unique arterial stem cell infusions. This medical landscape allows patients to access both intensive respiratory support and experimental therapies. These options are often unavailable in other regions.
Patient Consensus: Patients note it is important to start non-invasive ventilation early for better quality of life. In Korea, families should clarify emergency contact pathways. They should also ask how doctors explain the transition to long-term ventilation.
International patients can access amyotrophic lateral sclerosis (ALS) research and specialised therapies in South Korea. Facilities like Severance Hospital and Gachon University Gil Medical Center participate in global studies. Research initiatives like the Pan-Asian Consortium for Treatment and Research in ALS (PACTALS) facilitate regional trial access.
Bookimed Expert Insight: South Korea is a top-tier destination for neurological care. It ranks 6th globally by patient requests. Large hospitals like Severance manage 4,000,000 patients annually. In contrast, smaller VIP clinics such as RE:YOUTH limit intake to two patients daily. This allow patients to choose between high-volume research centres or personalised regenerative therapy environments.
Patient Consensus: Patients note that private treatment is accessible. However, joining a trial requires careful planning for repeated international travel. Long-term trials often have strict residency-based eligibility rules. Logistics like visa requirements and mobility support must be confirmed with the investigator before travelling to South Korea.